BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36059176)

  • 1. Assessment of VEGF and VEGF R1 serum levels in patients with neuroendocrine neoplasms before and after treatment with first-generation somatostatin analogues.
    Rosiek V; Janas K
    Endokrynol Pol; 2022; 73(3):612-618. PubMed ID: 36059176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues.
    Rosiek V; Janas K; Kos-Kudła B
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.
    Syguła A; Ledwon A; Hasse-Lazar K; Jurecka-Lubieniecka B; Michalik B; Paliczka-Cieślik E; Zeman M; Chmielik E; Sczasny J; Jarzab B; Handkiewicz-Junak D
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3841-3851. PubMed ID: 35503379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
    von Marschall Z; Scholz A; Cramer T; Schäfer G; Schirner M; Oberg K; Wiedenmann B; Höcker M; Rosewicz S
    J Natl Cancer Inst; 2003 Mar; 95(6):437-48. PubMed ID: 12644537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the Concentration of Endogenous Factors Regulating Angiogenesis, VASH-1 and VEGF-A, in the Blood Serum of Patients with Neuroendocrine Neoplasms.
    Strzelczyk J; Wójcik-Giertuga M; Cuber P; Biernacki K; Kos-Kudła B; Strzelczyk JK
    Biomed Res Int; 2022; 2022():9084393. PubMed ID: 35372578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.
    Kidd M; Modlin IM; Bodei L; Drozdov I
    Cell Mol Gastroenterol Hepatol; 2015 Mar; 1(2):131-153. PubMed ID: 28210673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Subtype classification and clinicopathological characteristics of gastric neuroendocrine neoplasms: an analysis of 241 cases].
    Zhang P; Zhang Y; Zhang C; Shi Y; Liu J; Liu Q; Yu L; Wang M; Zou G; Lou J; Chen J; Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1241-1246. PubMed ID: 27928793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
    Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
    Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival.
    Decaussin M; Sartelet H; Robert C; Moro D; Claraz C; Brambilla C; Brambilla E
    J Pathol; 1999 Aug; 188(4):369-77. PubMed ID: 10440746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
    Krug S; Mordhorst JP; Moser F; Theuerkorn K; Ruffert C; Egidi M; Rinke A; Gress TM; Michl P
    PLoS One; 2019; 14(6):e0218953. PubMed ID: 31237925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does combination of "cold" and "hot" somatostatin analogs prolong survival of patients with neuroendocrine neoplasms?
    Sowa-Staszczak A; Stefanska A; Chrapczynski P; Trofimiuk-Müldner M; Szura M; Hubalewska-Dydejczyk A
    Endocr J; 2017 Feb; 64(2):171-177. PubMed ID: 27853048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel non-invasive biomarkers of urinary chronic pelvic pain syndrome: findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network.
    Dagher A; Curatolo A; Sachdev M; Stephens AJ; Mullins C; Landis JR; van Bokhoven A; El-Hayek A; Froehlich JW; Briscoe AC; Roy R; Yang J; Pontari MA; Zurakowski D; Lee RS; Moses MA;
    BJU Int; 2017 Jul; 120(1):130-142. PubMed ID: 28263447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia effects on proangiogenic factors in human umbilical vein endothelial cells: functional role of the peptide somatostatin.
    Dal Monte M; Martini D; Ristori C; Azara D; Armani C; Balbarini A; Bagnoli P
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jun; 383(6):593-612. PubMed ID: 21523559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).
    Lopez CL; Joos B; Bartsch DK; Manoharan J; Albers M; Slater EP; Bollmann C; Roth S; Bayer A; Fendrich V
    World J Surg; 2019 Mar; 43(3):831-838. PubMed ID: 30600364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Circulating VEGF and its soluble receptor sVEGFR-1 in patients with lung cancer].
    Swidzińska E; Ossolińska M; Naumnik W; Izycki T; Kucejko W; Chyczewska E
    Pneumonol Alergol Pol; 2004; 72(9-10):389-94. PubMed ID: 16021992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?
    Körner M; Waser B; Reubi JC
    Neuroendocrinology; 2015; 101(1):45-57. PubMed ID: 25591947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in children with brain tumors.
    Sobol-Milejska G; Mizia-Malarz A; Musiol K; Chudek J; Bożentowicz-Wikarek M; Wos H; Mandera M
    Adv Clin Exp Med; 2017 Jul; 26(4):571-575. PubMed ID: 28691414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations.
    Flisiak I; Zaniewski P; Rogalska-Taranta M; Chodynicka B
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):302-7. PubMed ID: 21418334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.